A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes

被引：0
|
作者：
de Castro, C. [1 ]
Adams, D. [1 ]
Rizzieri, D. [1 ]
Moore, J. [1 ]
Gockerman, J. [1 ]
Diehl, L. [1 ]
Horwitz, M. [1 ]
Edmonds, E. [1 ]
Warzecho, J. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC 27706 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70210-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [41] DECITABINE IN TREATMENT OF PATIENTS WITH INTERMEDIATEOR HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Kalinichenko, E.
    Ponteleeva, I.
    Fiodarava, A.
    Iskrov, I.
    Uss, A.
    LEUKEMIA RESEARCH, 2017, 55 : S71 - S72
  • [42] Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
    Galimberti, Sara
    Guerrini, Francesca
    Salvi, Flavia
    Petrini, Iacopo
    Gioia, Daniela
    Messa, Emanuela
    Palumbo, Giuseppe A.
    Cilloni, Daniela
    Petrini, Mario
    Levis, Alessandro
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [43] Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
    Sara Galimberti
    Francesca Guerrini
    Flavia Salvi
    Iacopo Petrini
    Daniela Gioia
    Emanuela Messa
    Giuseppe A Palumbo
    Daniela Cilloni
    Mario Petrini
    Alessandro Levis
    Journal of Hematology & Oncology, 5
  • [44] Arsenic trioxide as a treatment for myelodysplastic syndrome
    Sekeres M.A.
    Current Hematologic Malignancy Reports, 2006, 1 (1) : 34 - 38
  • [45] Arsenic now in myelodysplastic syndromes
    Rousselot, Philippe
    HEMATOLOGIE, 2006, 12 (04): : 224 - 224
  • [46] Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes
    Qian, S.
    Duan, L.
    Zhu, Y.
    Hong, M.
    Zhang, R.
    Zhang, S.
    Liu, P.
    Lu, H.
    Wu, H.
    Qiu, H.
    Li, J.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S153
  • [47] NF-κB and FLEP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
    Kerbauy, DMB
    Lesnikov, V
    Abbasi, N
    Seal, S
    Scott, B
    Deeg, HJ
    BLOOD, 2005, 106 (12) : 3917 - 3925
  • [48] Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
    Zeidan, Amer M.
    Davidoff, Amy J.
    Long, Jessica B.
    Hu, Xin
    Wang, Rong
    Ma, Xiaomei
    Gross, Cary P.
    Abel, Gregory A.
    Huntington, Scott F.
    Podoltsev, Nikolai A.
    Hajime, Uno
    Prebet, Thomas
    Gore, Steven D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (05) : 829 - 840
  • [49] The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Cornelison, A. Megan
    Cortes, Jorge E.
    Ravandi, Farhad
    Daver, Naval
    Kadia, Tapan
    Teng, Angela
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 390 - 394
  • [50] Clinical Observation Of Decitabine Treatment In Selected Patients With Lower Risk Myelodysplastic Syndromes
    Chang, Chunkang
    Zhang, Zheng
    Zhao, Youshan
    Li, Xiao
    BLOOD, 2013, 122 (21)
12345